Skye Bioscience Also in Phase 2 for CB1 Inhibitor, Nimacimab, in Obesity

 

CBeyond™ will assess nimacimab’s ability to safely induce weight loss, and will also evaluate a combination of a GLP-1 receptor agonist plus nimacimab

https://www.globenewswire.com/news-release/2024/08/22/2934114/0/en/Skye-Bioscience-Launches-Phase-2-CBeyond-Clinical-Trial-of-its-Differentiated-CB1-Inhibitor-Nimacimab-in-Patients-with-Obesity.html